Q2 2022 13F Holders as of 30 Jun 2022
-
Type / Class
-
Equity / COM NEW
-
Total 13F shares
-
4,989,777
-
Share change
-
-408,729
-
Total reported value
-
$6,533,368
-
Put/Call ratio
-
59%
-
Price per share
-
$1.31
-
Number of holders
-
51
-
Value change
-
-$574,540
-
Number of buys
-
13
-
Number of sells
-
17
Institutional Holders of GALECTIN THERAPEUTICS INC - COM NEW (GALT) as of Q2 2022
As of 30 Jun 2022,
GALECTIN THERAPEUTICS INC - COM NEW (GALT) was held by
51 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
4,989,777 shares.
The largest 10 holders included
VANGUARD GROUP INC, GEODE CAPITAL MANAGEMENT, LLC, Geneos Wealth Management Inc., Atria Wealth Solutions, Inc., MILLENNIUM MANAGEMENT LLC, STATE STREET CORP, Cutter & CO Brokerage, Inc., Cambridge Investment Research Advisors, Inc., NORTHERN TRUST CORP, and MORGAN STANLEY.
This page lists
51
institutional shareholders reporting positions in this security
for the Q2 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.